Alliance Pharma plc (AIM: APH), the international healthcare group, announces its unaudited trading update for the year ended 31 December 2019 ahead of the announcement of the Group’s audited results on 24 March 2020.
Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce its interim results for the six months ended 30 June 2019.
Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce its pre-close trading update for the six months ended 30 June 2019, which shows strong revenue growth and leverage below 2.0 times.
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that John Dawson, Non-Executive Director, Founder and former CEO of Alliance, has decided to step down from the Company’s Board, effective from 30 June 2019, after 23 years of service.
Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce its preliminary results for the year ended 31 December 2018.
Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical company, announces that it has today launched Xonvea, its prescription product for the treatment of nausea and vomiting of pregnancy (NVP), in the UK. Xonvea is a new licensed medicine available in the UK for women with NVP where conservative management has failed.
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2018.
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV (a member of the Johnson & Johnson group of companies) for a total consideration of £60.0 million.